Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium (68Ga) boclatixafortide
- Development stage
- Unknown
- Lead developer
- Pentixapharm
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Gallium (68Ga) boclatixafortide (PentixaFor) is a gallium-68-labeled radiopharmaceutical diagnostic imaging agent that targets the C-X-C chemokine receptor type 4 (CXCR4). It is a cyclic pentapeptide conjugated to a DOTA chelator and radiolabeled with the positron-emitting isotope gallium-68. PentixaFor is developed by Pentixapharm (a spin-off of Eckert & Ziegler) for positron emission tomography (PET) imaging. It is primarily being developed for the diagnosis and subtyping of primary aldosteronism (PA) in patients with hypertension, as well as for staging and monitoring of hematological malignancies such as multiple myeloma, marginal zone lymphoma, and central nervous system lymphoma, and other CXCR4-expressing conditions like Cushing's syndrome.
- Brand names
- PentixaFor
- Other names
- 68Ga-Pentixafor68Ga-boclatixafortideGallium-68 CXCR4Gallium68 CXCR4Gallium 68 CXCR4[68Ga]Ga-PentixaForgallium (68Ga) pentixaforgallium Ga 68-pentixafor
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on gallium (68Ga) boclatixafortide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium (68Ga) boclatixafortide.